Daratumumab in transfusion‐dependent patients with low or intermediate‐ 1 risk myelodysplastic syndromes-Reference-Cited by-同舟云学术

Daratumumab in transfusion‐dependent patients with low or intermediate‐ 1 risk myelodysplastic syndromes

Published:2021-01-31 Issue:4 Volume:96 Page:
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Garcia‐Manero Guillermo¹^ORCID,Diez‐Campelo Maria²^ORCID,Vellenga Edo³,Jacoby Meagan A.⁴,Merchan Brayan⁵,Breems Dimitri⁶,Cortelezzi Agostino⁷,Doronin Vadim⁸,Gomez Valle⁹,Beckers Marielle¹⁰,Della Porta Matteo Giovanni¹¹,Varsos Helen¹²,Xiu Liang¹²,DeAngelis Nikki¹³,Nnane Ivo¹³,Rose Esther¹²,Eygen Koen¹⁴

Affiliation:

1. The University of Texas MD Anderson Cancer Center Houston Texas USA

2. Hospital Clinico Universitario de Salamanca Salamanca Spain

3. Department of Hematology, University Medical Center Groningen University of Groningen Groningen The Netherlands

4. Washington University School of Medicine St. Louis Missouri USA

5. Vall d'Hebron Institute of Oncology Barcelona Spain

6. Ziekenhuis Netwerk Antwerpen Antwerp Belgium

7. Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico and University of Milano Milan Italy

8. City Clinical Hospital #40 Moscow Russia

9. Hospital Universitario de La Princesa Madrid Spain

10. University Hospital Leuven Leuven Belgium

11. Humanitas Clinical and Research Center – IRCCS Humanitas Cancer Center Rozzano Italy